Lobbying client · LD-2 disclosures
Quva Pharma, Inc.
Texas
12 filings from 2 registrants · 2023–2026 · latest filed Jul 17, 2026
Reported on its behalf
$560K
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$560K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Pharmacy
PHA
9 filings
$450K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
Bills named in the filings
Every bill reference extracted from the filings' activity descriptions.
- S. 3794 119th CongressSAFE Drugs Act of 20261 filingthrough 2026
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Who did the lobbying
Every lobbyist named on this client's filings.
- Emily Austen Katz Prime Policy GroupCovered position: 2013-15: Senior Health Policy Advisor, Sen. Barbara Boxer; 2010-13: Health Policy Director, Rep. Diana DeGette; 2009-10: Legislative Assistant, Sen. Ron Wyden; 2005-07: Legislative Aide, Sen. Ron Wyden; 2004: Biomedical Ethics Intern (Paid), NIH6 filingsthrough 2024
- Emily Austen Katz Van Scoyoc AssociatesCovered position: Senior Health Policy Advisor, Senator Barbara Boxer; Health Policy Director, Representative Diana DeGette; Legislative Assistant, Senator Ron Wyden; and Legislative Aide, Senator Ron Wyden5 filingsthrough 2026
- Mitchell Vakerics Prime Policy GroupCovered position: 2007-08: Staff Assistant, Rep. Timothy Murphy; 2008-09: Legislative Correspondent/Press Assistant, Rep. Timothy Murphy; 2011-15: Legislative Counsel, Rep. Renee Ellmers; 2015: Legislative Director, Rep. Renee Ellmers
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: quva-pharma-inc.